Opinion|Videos|July 29, 2024

How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.

Video content above is prompted by the following question(s):

  • How do you balance the potential clinical benefits of CDK4/6 inhibitors with the cost considerations when making treatment decisions for early breast cancer patients?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo